Key terms
About SDGR
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SDGR news
Yesterday
9:55am ET
Maintaining Neutral: Assessing Schrodinger’s Mixed Q1 Performance and Future Outlook
May 02
8:50am ET
Schrodinger price target lowered to $30 from $35 at Craig-Hallum
May 02
7:35am ET
Maintaining Buy Rating on Schrodinger: Solid Fundamentals and Promising Pipeline Despite Quarterly Miss
May 02
6:23am ET
Maintained Buy Rating on Schrodinger: Navigating Short-Term Hurdles with Long-Term Catalysts in Sight
May 02
6:21am ET
Schrodinger price target lowered to $37 from $39 at Citi
May 01
5:00pm ET
Schrodinger backs FY24 software revenue growth view of 6%-13%
May 01
4:59pm ET
Schrodinger sees Q2 software revenue $31M-$33M vs. $33.4M in Q1
May 01
4:03pm ET
Schrodinger reports Q1 EPS (76c), consensus (75c)
Apr 04
9:10am ET
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA) and Schrodinger (SDGR)
Apr 04
8:20am ET
Analysts Conflicted on These Healthcare Names: Icon (ICLR), Schrodinger (SDGR) and Azenta (AZTA)
Feb 29
7:47am ET
Piper Sandler Keeps Their Buy Rating on Schrodinger (SDGR)
Feb 29
7:44am ET
Schrodinger price target lowered to $50 from $60 at Piper Sandler
Feb 29
7:29am ET
Buy Rating Affirmed for Schrodinger Amidst Robust Software Business and Promising Clinical Milestones
Feb 29
6:52am ET
Schrodinger price target lowered to $33 from $38 at KeyBanc
Feb 29
6:19am ET
Schrodinger price target lowered to $39 from $47 at Citi
Feb 29
5:29am ET
Schrodinger: A Neutral Rating with Revised Price Objective Amidst Growth Uncertainties
Feb 29
4:15am ET
Maintaining a Neutral Stance on Schrodinger Amidst Growth and Uncertainties
Feb 29
2:51am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Schrodinger (SDGR), Editas Medicine (EDIT) and MacroGenics (MGNX)
Feb 28
9:20pm ET
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Schrodinger (SDGR)
Feb 28
5:51pm ET
Schrodinger files automatic mixed securities shelf
Feb 28
4:23pm ET
Schrodinger sees FY24 software revenue growth up 6%-13%
Feb 28
4:22pm ET
Schrodinger reports Q4 EPS (32c), consensus (38c)
Feb 26
9:06am ET
Craig-Hallum Sticks to Their Buy Rating for Schrodinger (SDGR)
No recent press releases are available for SDGR
SDGR Financials
Key terms
Ad Feedback
SDGR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SDGR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
